FDA Clearance Tracker · P220026-S001
Symplicity Spyral Multi-Electrode Renal Denervation Catheter, Symplicity G3 Renal Devervation RF Generator
Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Feb 15, 2024
Approved
Time to decision
59 days
Received Dec 18, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P220026-S001
- Device name
- Symplicity Spyral Multi-Electrode Renal Denervation Catheter, Symplicity G3 Renal Devervation RF Generator
- Applicant
- Medtronic, Inc.
- Applicant location
- Santa Rosa, CA
- Received
- Dec 18, 2023
- Decided
- Feb 15, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P220026
Device type
- Device type
- Ablation catheter, renal denervation (QYI)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval of the protocol for the post-approval study Spyral AFFIRM (New-Enrollment Registry Study)
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.